HIV vaccine - Biosantech

Drug Profile

HIV vaccine - Biosantech

Alternative Names: HIV-1 vaccine - Biosantech; Tat Oyi

Latest Information Update: 21 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS; Universite de la Mediterranee
  • Developer Biosantech
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV-1 infections

Most Recent Events

  • 15 Mar 2016 Biosantech announces intention to submit MAA to European Union in second half of 2018
  • 15 Mar 2016 Interim efficacy and adverse events data from a phase IIa trial in HIV-1 infections released by Biosantech
  • 15 Mar 2016 Biosantech plans a phase III pivotal trial for HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top